

MOG-IgG in NMO and related disorders: a multicenter study
Brainstem involvement - frequency, presentation and outcome

Journal of Neuroinflammation

13, 281

DOI: [10.1186/s12974-016-0719-z](https://doi.org/10.1186/s12974-016-0719-z)

Citation Report

#	ARTICLE	IF	CITATIONS
1	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. <i>Journal of Neuroinflammation</i> , 2016, 13, 279.	3.1	351
2	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. <i>Journal of Neuroinflammation</i> , 2016, 13, 280.	3.1	686
3	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. <i>Journal of Neuroinflammation</i> , 2016, 13, 282.	3.1	217
4	Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy. <i>Journal of Neuroinflammation</i> , 2016, 13, 278.	3.1	23
6	Failure of alemtuzumab therapy to control MOG encephalomyelitis. <i>Neurology</i> , 2017, 89, 207-209.	1.5	27
7	NMO Spectrum Disorders. <i>Neurology International Open</i> , 2017, 01, E36-E47.	0.4	3
8	Devic's disease before Devic: On the contribution of Friedrich Albin Schanz (1863â€“1923). <i>Journal of the Neurological Sciences</i> , 2017, 379, 99-102.	0.3	6
9	Differential diagnosis of neuromyelitis optica spectrum disorders. <i>Therapeutic Advances in Neurological Disorders</i> , 2017, 10, 265-289.	1.5	80
10	Myelin oligodendrocyte glycoprotein antibodies: How clinically useful are they?. <i>Current Opinion in Neurology</i> , 2017, 30, 295-301.	1.8	92
11	Neuromyelitis Spectrum Disorders. <i>Mayo Clinic Proceedings</i> , 2017, 92, 663-679.	1.4	224
12	The MRZ reaction as a highly specific marker of multiple sclerosis: re-evaluation and structured review of the literature. <i>Journal of Neurology</i> , 2017, 264, 453-466.	1.8	105
13	Pediatric Optic Neuritis: What Is New. <i>Journal of Neuro-Ophthalmology</i> , 2017, 37, S14-S22.	0.4	25
14	Diffusion tensor imaging for multilevel assessment of the visual pathway: possibilities for personalized outcome prediction in autoimmune disorders of the central nervous system. <i>EPMA Journal</i> , 2017, 8, 279-294.	3.3	35
15	Vitamin D in the prevention, prediction and treatment of neurodegenerative and neuroinflammatory diseases. <i>EPMA Journal</i> , 2017, 8, 313-325.	3.3	94
17	Influence of type I IFN signaling on anti-MOG antibody-mediated demyelination. <i>Journal of Neuroinflammation</i> , 2017, 14, 127.	3.1	15
19	Pattern Recognition of the Multiple Sclerosis Syndrome. <i>Brain Sciences</i> , 2017, 7, 138.	1.1	22
20	Myelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating Diseases. <i>Frontiers in Immunology</i> , 2017, 8, 529.	2.2	184
21	Pattern II and pattern III MS are entities distinct from pattern I MS: evidence from cerebrospinal fluid analysis. <i>Journal of Neuroinflammation</i> , 2017, 14, 171.	3.1	34

#	ARTICLE	IF	CITATIONS
22	Investigational drugs in development to prevent neuromyelitis optica relapses. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 265-271.	1.9	40
23	Mechanisms for lesion localization in neuromyelitis optica spectrum disorders. <i>Current Opinion in Neurology</i> , 2018, 31, 325-333.	1.8	48
24	The current role of MRI in differentiating multiple sclerosis from its imaging mimics. <i>Nature Reviews Neurology</i> , 2018, 14, 199-213.	4.9	157
25	Defining distinct features of anti-MOG antibody associated central nervous system demyelination. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628641876208.	1.5	137
26	Neuroimmunological Registries in Germany. <i>Neurology International Open</i> , 2018, 02, E25-E39.	0.4	9
27	Multiple Sclerosis: Eyes on the Future. <i>Journal of Neuro-Ophthalmology</i> , 2018, 38, 81-84.	0.4	5
29	CLIPPERS mimickers: relapsing brainstem encephalitis associated with anti-MOG antibodies. <i>European Journal of Neurology</i> , 2018, 25, e16-e17.	1.7	20
30	Magnetic resonance imaging findings at the first episode of acute optic neuritis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, 30-36.	0.9	23
31	MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature. <i>Journal of Neuroinflammation</i> , 2018, 15, 88.	3.1	52
32	Clinical characteristics of myelin oligodendrocyte glycoprotein seropositive optic neuritis: a cohort study in Shanghai, China. <i>Journal of Neurology</i> , 2018, 265, 33-40.	1.8	74
33	Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 127-137.	0.9	422
34	Seizures and Encephalitis in Myelin Oligodendrocyte Glycoprotein IgG Disease vs Aquaporin 4 IgG Disease. <i>JAMA Neurology</i> , 2018, 75, 65.	4.5	184
35	Leptomeningeal and Intraparenchymal Blood Barrier Disruption in a MOG-IgG-Positive Patient. <i>Case Reports in Neurological Medicine</i> , 2018, 2018, 1-3.	0.3	7
36	CSF-S100B Is a Potential Candidate Biomarker for Neuromyelitis Optica Spectrum Disorders. <i>BioMed Research International</i> , 2018, 2018, 1-11.	0.9	13
37	Anti-Myelin Oligodendrocyte Glycoprotein and Human Leukocyte Antigens as Markers in Pediatric and Adolescent Multiple Sclerosis: on Diagnosis, Clinical Phenotypes, and Therapeutic Responses. <i>Multiple Sclerosis International</i> , 2018, 2018, 1-9.	0.4	9
39	The first Japanese report on neuromyelitis optica rediscovered: acute bilateral blindness, tetraparesis and respiratory insufficiency in a 35-year-old man (1891). <i>Journal of the Neurological Sciences</i> , 2018, 395, 121-125.	0.3	4
40	The clinical features, underlying immunology, and treatment of autoantibody-mediated movement disorders. <i>Movement Disorders</i> , 2018, 33, 1376-1389.	2.2	44
41	Pain in AQP4-IgG-positive and MOG-IgG-positive neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018, 4, 205521731879668.	0.5	40

#	ARTICLE	IF	CITATIONS
42	Clinical utility of anti-MOG antibody testing in a Danish cohort. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 26, 61-67.	0.9	10
43	Neuromyelitis optica spectrum disorders and pregnancy: relapse-preventive measures and personalized treatment strategies. <i>EPMA Journal</i> , 2018, 9, 249-256.	3.3	31
45	Neuroimaging in Pediatric Autoimmune Diseases. <i>Journal of Pediatric Neurology</i> , 2018, 16, 171-184.	0.0	1
46	MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 25, 66-72.	0.9	158
47	Progressive Demyelination in the Presence of Serum Myelin Oligodendrocyte Glycoprotein-IgG: A Case Report. <i>Frontiers in Neurology</i> , 2018, 9, 340.	1.1	5
48	Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders. <i>JAMA Neurology</i> , 2018, 75, 1355.	4.5	286
49	Autoimmune and Paraneoplastic Myelopathies. <i>Seminars in Neurology</i> , 2018, 38, 278-289.	0.5	21
50	MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder. <i>Frontiers in Neurology</i> , 2018, 9, 217.	1.1	156
51	Bal ³ 's concentric sclerosis is immunologically distinct from multiple sclerosis: results from retrospective analysis of almost 150 lumbar punctures. <i>Journal of Neuroinflammation</i> , 2018, 15, 22.	3.1	32
52	Epidemiology of neuromyelitis optica spectrum disorder. <i>Acta Neurologica Scandinavica</i> , 2018, 137, 626-627.	1.0	1
53	MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. <i>Journal of Neuroinflammation</i> , 2018, 15, 134.	3.1	563
54	Neuromyelitis Optica Spectrum Disorders. , 2018, , 313-335.		1
55	Optical coherence tomography in acute optic neuritis: A population-based study. <i>Acta Neurologica Scandinavica</i> , 2018, 138, 566-573.	1.0	44
56	Clinical characteristics and prognosis of myelin oligodendrocyte glycoprotein antibody-seropositive paediatric optic neuritis in China. <i>British Journal of Ophthalmology</i> , 2019, 103, 831-836.	2.1	44
57	Neuromyelitis Optica Spectrum Disorders. , 2019, , 187-195.		0
58	Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. <i>Journal of Neuroinflammation</i> , 2019, 16, 134.	3.1	115
59	Collaborative International Research in Clinical and Longitudinal Experience Study in NMOSD. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e583.	3.1	33
60	Two Japanese cases of anti-MOG antibody-associated encephalitis that mimicked neuro-Behçet's disease. <i>Journal of Neuroimmunology</i> , 2019, 334, 577002.	1.1	12

#	ARTICLE	IF	CITATIONS
61	Cerebellar lesions in a patient with anti-myelin oligodendrocyte glycoprotein antibody-associated encephalitis. <i>Clinical and Experimental Neuroimmunology</i> , 2019, 10, 264-266.	0.5	4
62	The spectrum of immune-mediated and inflammatory lesions of the brainstem. <i>Neurology</i> , 2019, 93, 390-405.	1.5	22
63	The imbalance between regulatory and memory B cells accompanied by an increased number of circulating T-follicular helper cells in MOG-antibody-associated demyelination. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 36, 101397.	0.9	18
64	Unfavorable Structural and Functional Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis. <i>Journal of Neuro-Ophthalmology</i> , 2019, 39, 3-7.	0.4	20
65	Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines. <i>Brain</i> , 2019, 142, 1858-1875.	3.7	303
66	Neuromyelitis Optica Spectrum Disorder and Anti-MOG Syndromes. <i>Biomedicines</i> , 2019, 7, 42.	1.4	90
67	Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. <i>Journal of Clinical Apheresis</i> , 2019, 34, 171-354.	0.7	1,263
68	Cognitive Impairment in Neuromyelitis Optica Spectrum Disorders: A Review of Clinical and Neuroradiological Features. <i>Frontiers in Neurology</i> , 2019, 10, 608.	1.1	42
69	Epidemiology of neuromyelitis optica spectrum disorder in Denmark (1998–2008, 2007–2014). <i>Brain and Behavior</i> , 2019, 9, e01338.	1.0	12
70	MOG antibody seropositive aseptic meningitis: A new clinical phenotype. <i>Journal of Neuroimmunology</i> , 2019, 333, 476960.	1.1	36
72	Autoantibodies against Neurologic Antigens in Nonneurologic Autoimmunity. <i>Journal of Immunology</i> , 2019, 202, 2210-2219.	0.4	22
73	Myelinoclastic diffuse sclerosis (Schilder's disease) is immunologically distinct from multiple sclerosis: results from retrospective analysis of 92 lumbar punctures. <i>Journal of Neuroinflammation</i> , 2019, 16, 51.	3.1	16
74	Comparison of Ocular Motor Findings Between Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis Involving the Brainstem and Cerebellum. <i>Cerebellum</i> , 2019, 18, 511-518.	1.4	8
75	Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders. <i>Brain</i> , 2019, 142, 1310-1323.	3.7	131
76	The history of neuromyelitis optica. Part 2: "Spinal amaurosis", or how it all began. <i>Journal of Neuroinflammation</i> , 2019, 16, 280.	3.1	32
77	What You Need to Know About AQP4, MOG, and NMOSD. <i>Seminars in Neurology</i> , 2019, 39, 718-731.	0.5	34
78	Myelin oligodendrocyte glycoprotein antibodies in neurological disease. <i>Nature Reviews Neurology</i> , 2019, 15, 89-102.	4.9	439
79	Area postrema syndrome: A short history of a pearl in demyelinating diseases. <i>Multiple Sclerosis Journal</i> , 2019, 25, 325-329.	1.4	19

#	ARTICLE	IF	CITATIONS
80	Sex differences in autoimmune disorders of the central nervous system. <i>Seminars in Immunopathology</i> , 2019, 41, 177-188.	2.8	74
81	Clinical spectrum of inflammatory central nervous system demyelinating disorders associated with antibodies against myelin oligodendrocyte glycoprotein. <i>Neurochemistry International</i> , 2019, 130, 104319.	1.9	35
82	Bilateral trigeminal root entry zone enhancement in MOG-IgG-associated brainstem encephalitis. <i>Neurological Sciences</i> , 2019, 40, 1083-1085.	0.9	12
83	Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations. <i>Practical Neurology</i> , 2019, 19, 187-195.	0.5	78
84	The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. <i>Multiple Sclerosis Journal</i> , 2020, 26, 806-814.	1.4	150
85	Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibody Diseases. <i>Annals of Neurology</i> , 2020, 87, 256-266.	2.8	100
86	Rituximab in children with myelin oligodendrocyte glycoprotein antibody and relapsing neuroinflammatory disease. <i>Developmental Medicine and Child Neurology</i> , 2020, 62, 390-395.	1.1	20
87	Deciphering anti-MOG IgG antibodies: Clinical and radiological spectrum, and comparison of antibody detection assays. <i>Journal of the Neurological Sciences</i> , 2020, 410, 116673.	0.3	12
88	Quantitative brain lesion distribution may distinguish MOG-ab and AQP4-ab neuromyelitis optica spectrum disorders. <i>European Radiology</i> , 2020, 30, 1470-1479.	2.3	11
89	Neuromyelitis optica. <i>Nature Reviews Disease Primers</i> , 2020, 6, 85.	18.1	232
90	Brainstem Encephalitis. The Role of Imaging in Diagnosis. <i>Current Problems in Diagnostic Radiology</i> , 2021, 50, 946-960.	0.6	9
91	E.U. paediatric MOG consortium consensus: Part 1 – Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. <i>European Journal of Paediatric Neurology</i> , 2020, 29, 2-13.	0.7	87
92	Understanding Pediatric Neuroimmune Disorder Conflicts: A Neuroradiologic Approach in the Molecular Era. <i>Radiographics</i> , 2020, 40, 1395-1411.	1.4	8
93	Recent developments in MOG-IgG associated neurological disorders. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642094513.	1.5	45
94	Differences in Advanced Magnetic Resonance Imaging in MOG-IgG and AQP4-IgG Seropositive Neuromyelitis Optica Spectrum Disorders: A Comparative Study. <i>Frontiers in Neurology</i> , 2020, 11, 499910.	1.1	14
95	Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients. <i>Journal of Neuroinflammation</i> , 2020, 17, 261.	3.1	84
96	Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients. <i>Journal of Neuroinflammation</i> , 2020, 17, 262.	3.1	44
97	The Expanding Clinical Spectrum of Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Associated Disease in Children and Adults. <i>Frontiers in Neurology</i> , 2020, 11, 960.	1.1	25

#	ARTICLE	IF	CITATIONS
98	Area Postrema Syndrome: A Rare Feature of Chronic Lymphocytic Inflammation With Pontine Perivascular Enhancement Responsive to Steroids. <i>Frontiers in Neurology</i> , 2020, 11, 730.	1.1	6
99	Pain in NMOSD and MOGAD: A Systematic Literature Review of Pathophysiology, Symptoms, and Current Treatment Strategies. <i>Frontiers in Neurology</i> , 2020, 11, 778.	1.1	37
100	Spinal Cord Involvement in MS and Other Demyelinating Diseases. <i>Biomedicines</i> , 2020, 8, 130.	1.4	9
101	Visualizing the Central Nervous System: Imaging Tools for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders. <i>Frontiers in Neurology</i> , 2020, 11, 450.	1.1	29
102	Value of Area Postrema Syndrome in Differentiating Adults With AQP4 vs. MOG Antibodies. <i>Frontiers in Neurology</i> , 2020, 11, 396.	1.1	23
103	Imaging of Neuromyelitis Optica Spectrum Disorders. <i>Seminars in Ultrasound, CT and MRI</i> , 2020, 41, 319-331.	0.7	2
104	Evaluation of efficacy and tolerability of first-line therapies in NMOSD. <i>Neurology</i> , 2020, 94, e1645-e1656.	1.5	66
105	Linear pontine trigeminal root lesion in a patient with anti-myelin oligodendrocyte glycoprotein antibody-associated encephalitis. <i>Clinical and Experimental Neuroimmunology</i> , 2020, 11, 122-125.	0.5	1
106	Myelin oligodendrocyte glycoprotein antibody associated central nervous system demyelinating disease: a tertiary center experience from Turkey. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102376.	0.9	8
107	Cell-based assays for the detection of MOG antibodies: a comparative study. <i>Journal of Neurology</i> , 2020, 267, 3555-3564.	1.8	44
108	Binding patterns and functional properties of human antibodies to AQP4 and MOG on murine optic nerve and retina. <i>Journal of Neuroimmunology</i> , 2020, 342, 577194.	1.1	2
109	S1 guidelines -lumbar puncture and cerebrospinal fluid analysis-(abridged and translated version). <i>Neurological Research and Practice</i> , 2020, 2, 8.	1.0	23
110	Area postrema syndrome as initial manifestation in neuromyelitis optica spectrum disorder patients: A retrospective study. <i>Revue Neurologique</i> , 2021, 177, 400-406.	0.6	10
111	MOG-expressing teratoma followed by MOG-IgG-positive optic neuritis. <i>Acta Neuropathologica</i> , 2021, 141, 127-131.	3.9	21
112	MRI characteristics of MOG-Ab associated disease in adults: An update. <i>Revue Neurologique</i> , 2021, 177, 39-50.	0.6	15
113	Clinical spectrum, treatment and outcome of myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease in children: a tertiary care experience. <i>Acta Neurologica Belgica</i> , 2021, 121, 231-239.	0.5	6
114	Dysphagia in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody disease as a surrogate of brain involvement?. <i>European Journal of Neurology</i> , 2021, 28, 1765-1770.	1.7	10
115	Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disorder-optic neuritis: a comprehensive review of diagnosis and treatment. <i>Eye</i> , 2021, 35, 753-768.	1.1	35

#	ARTICLE	IF	CITATIONS
117	Anaplastic ganglioglioma originating from the medulla oblongata: case report. <i>Translational Cancer Research</i> , 2021, 10, 3059-3066.	0.4	1
118	Myelin Oligodendrocyte Glycoprotein (MOG)-IgG associated demyelinating disease: Our experience with this distinct syndrome. <i>Annals of Indian Academy of Neurology</i> , 2021, 24, 69.	0.2	6
119	Pain, depression, and quality of life in adults with MOG-antibody-associated disease. <i>European Journal of Neurology</i> , 2021, 28, 1645-1658.	1.7	11
121	Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies. <i>Frontiers in Immunology</i> , 2021, 12, 647618.	2.2	32
123	MOG-IgG Associated Disease (MOG-AD) in Adults. <i>Current Treatment Options in Neurology</i> , 2021, 23, 1.	0.7	1
124	Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis—A Review. <i>Journal of Neuro-Ophthalmology</i> , 2021, Publish Ahead of Print, e786-e795.	0.4	0
125	The Clinical Features of FLAIR-Hyperintense Lesions in Anti-MOG Antibody Associated Cerebral Cortical Encephalitis with Seizures: Case Reports and Literature Review. <i>Frontiers in Immunology</i> , 2021, 12, 582768.	2.2	14
126	Clinical and neuroimaging findings in MOGAD—MRI and OCT. <i>Clinical and Experimental Immunology</i> , 2021, 206, 266-281.	1.1	24
127	Autoimmune Brainstem Encephalitis: An Illustrative Case and a Review of the Literature. <i>Journal of Clinical Medicine</i> , 2021, 10, 2970.	1.0	8
128	Modeling compartmentalized chronic immune-mediated demyelinating CNS disease in the Biozzi ABH mouse. <i>Journal of Neuroimmunology</i> , 2021, 356, 577582.	1.1	3
129	Aseptic meningitis and leptomeningeal enhancement associated with anti-MOG antibodies: A review. <i>Journal of Neuroimmunology</i> , 2021, 358, 577653.	1.1	18
130	Neuromyelitis optica with brain stem involvement in a middle-aged Ethiopian woman: a case report and review of literature. <i>Journal of Medical Case Reports</i> , 2021, 15, 489.	0.4	0
131	Five-year visual outcomes after optic neuritis in anti-MOG antibody-associated disease. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103222.	0.9	14
132	Treatment of MOG-IgG associated disease in paediatric patients: A systematic review. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103216.	0.9	10
133	Special Findings in Neurogenic Dysphagia. , 2021, , 109-222.		1
134	Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients. <i>Journal of the Neurological Sciences</i> , 2017, 381, 240-244.	0.3	29
136	MRI Characteristics of NMO, MOG and MS Related Optic Neuritis. <i>Seminars in Ophthalmology</i> , 2020, 35, 333-342.	0.8	25
137	Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 384-390.	0.9	55

#	ARTICLE	IF	CITATIONS
139	Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Current Insights into the Disease Pathophysiology, Diagnosis and Management. International Journal of Molecular Sciences, 2021, 22, 100.	1.8	74
140	Lessons of the month 1: A case of rhombencephalitis as a rare complication of acute COVID-19 infection. Clinical Medicine, 2020, 20, 293-294.	0.8	99
141	Paraneoplastic encephalomyelorradiculitis with multiple autoantibodies against ITPR-1, GFAP and MOG: case report and literature review. Neurological Research and Practice, 2021, 3, 48.	1.0	11
142	Mit Schluckst�rungen assoziierte Erkrankungen. , 2018, , 69-133.		0
144	Anti-MOG Diseases. , 2020, , 95-108.		0
145	Area postrema syndrome in neuromyelitis optica spectrum disorder: diagnostic challenges and descriptive patterns. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2021, 57, .	0.4	2
146	Prodromal emesis in MOG-antibody associated disorder. Multiple Sclerosis and Related Disorders, 2022, 58, 103463.	0.9	3
147	Autoimmune Brainstem Encephalitis. , 2022, , 368-390.		0
148	Acute Disseminated Encephalomyelitis and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. , 2022, , 290-314.		0
149	Dysphagia in Neuroinflammatory Diseases of the Central Nervous System. , 0, , .		0
150	Case Report: Four Cases of Cortical/Brainstem Encephalitis Positive for Myelin Oligodendrocyte Glycoprotein Immunoglobulin G. Frontiers in Neurology, 2021, 12, 775181.	1.1	3
151	Frequently Asked Questions on Autoimmune Encephalitis and Related Disorders. , 2022, , 630-655.		1
152	Neuromyelitis Optica Spectrum Disorders and Glial Fibrillary Acidic Protein Autoimmunity. , 2022, , 315-341.		0
153	Sleep and Autoimmunity. , 2022, , 563-587.		0
154	MOG antibody-associated encephalomyelitis mimicking bacterial meningomyelitis following ChAdOx1 nCoV-19 vaccination: a case report. Therapeutic Advances in Neurological Disorders, 2022, 15, 175628642110706.	1.5	8
155	Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder. Journal of the Korean Neurological Association, 2022, 40, 15-21.	0.0	0
157	Recurrence of Anti-N-Methyl-D-Aspartate Receptor Encephalitis: A Cohort Study in Central China. Frontiers in Neurology, 2022, 13, 832634.	1.1	3
158	MOG antibody disease with ovarian teratoma: A case report and review of the literature. Journal of Neuroimmunology, 2022, 367, 577858.	1.1	2

#	ARTICLE	IF	CITATIONS
159	Clinical Profile and Treatment Outcome in MOGAD: A Single-Center Case-Series Study in Guiyang, China. <i>Frontiers in Neurology</i> , 2022, 13, 830488.	1.1	3
161	Rare nervous system involvement in an anti-myelin oligodendrocyte-positive case: spinal leptomeningeal involvement. <i>Journal of Surgery and Medicine</i> , 2022, 6, 1-1.	0.0	0
162	COVID-19 Vaccineâ€”A Potential Trigger for MOGAD Transverse Myelitis in a Teenagerâ€”A Case Report and a Review of the Literature. <i>Children</i> , 2022, 9, 674.	0.6	4
163	Ovarian Teratoma-Related Paraneoplastic Neurological Syndromes. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	4
164	A MOG antibodyâ€”related disorder associated with peripheral facial nerve palsy. <i>Clinical and Experimental Neuroimmunology</i> , 0, , .	0.5	0
166	MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature. <i>Journal of Neurology</i> , 2022, 269, 5198-5212.	1.8	32
167	Multiple sclerosis and neuromyelitis optica spectrum disorders. , 2023, , 575-608.		1
168	Inositol 1,4,5-trisphosphate receptor type 1 autoantibody (ITPR1-IgG/anti-Sj)-associated autoimmune cerebellar ataxia, encephalitis and peripheral neuropathy: review of the literature. <i>Journal of Neuroinflammation</i> , 2022, 19, .	3.1	6
169	Multiple Sclerosis and related disorders. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2022, , 177-200.	1.0	4
170	Diplopia, COVID-19 and Vaccination: Results from a Cross-Sectional Study in Croatia. <i>Vaccines</i> , 2022, 10, 1558.	2.1	0
171	Impaired response of blood neutrophils to cell-death stimulus differentiates AQP4-IgG-seropositive NMOSD from MOGAD. <i>Journal of Neuroinflammation</i> , 2022, 19, .	3.1	6
172	Neurologic autoimmune diseases. , 2022, , 887-975.		0
173	Lesion follows function: video-oculography compared with MRI to diagnose internuclear ophthalmoplegia in patients with multiple sclerosis. <i>Journal of Neurology</i> , 0, , .	1.8	0
174	Astrocytoma with myelin oligodendrocyte glycoprotein antibody associated encephalomyelitis: A case report. <i>Medicine (United States)</i> , 2022, 101, e31003.	0.4	1
176	Prognostic relevance of quantitative and longitudinal MOG antibody testing in patients with MOGAD: a multicentre retrospective study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2023, 94, 201-210.	0.9	18
177	High fever in myelin oligodendrocyte glycoprotein-associated disorder (MOGAD): A diagnostic challenge. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2023, 9, 205521732211489.	0.5	0
178	A rare case of a wall-eyed bilateral internuclear ophthalmoplegia (WEBINO) syndrome in a patient with cutaneous lupus erythematosus after COVID-19 infection. <i>Journal of Neurology</i> , 2023, 270, 1224-1228.	1.8	1
179	<sc>Nonâ€”ADEM</sc> encephalitis in patients with myelin oligodendrocyte glycoprotein antibodies: a systematic review. <i>European Journal of Neurology</i> , 2023, 30, 1515-1527.	1.7	6

#	ARTICLE	IF	CITATIONS
180	Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Diseases. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2023, 10, .	3.1	7
181	Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. <i>Lancet Neurology</i> , The, 2023, 22, 268-282.	4.9	250
182	Unilateral Autoimmune Encephalitis: A Case Report on a Rare Manifestation of Myelin Oligodendrocyte Glycoprotein Antibody Disease. <i>Cureus</i> , 2023, , .	0.2	0
183	Area postrema syndrome with linear enhancement along the surface of the brainstem and fourth ventricle in autoimmune GFAP astrocytopathy. <i>BMC Neurology</i> , 2023, 23, .	0.8	0
184	Guidelines on the Use of Therapeutic Apheresis in Clinical Practice â€“ Evidenceâ€Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. <i>Journal of Clinical Apheresis</i> , 2023, 38, 77-278.	0.7	81
185	Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD)â€“ revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis. <i>Journal of Neurology</i> , 2023, 270, 3341-3368.	1.8	23
195	Coexistence of longitudinally extensive transverse myelitis and diffuse midline glioma in the brainstem in an adolescent boy with acute flaccid paralysis. <i>Child's Nervous System</i> , 0, , .	0.6	0
202	Mit SchluckstÃrungen assoziierte Erkrankungen. , 2024, , 81-155.		0